Use of the Patient Benefit Index to monitor treatment of chronic spontaneous urticaria with omalizumab
Publikation: Bidrag til tidsskrift › Letter › fagfællebedømt
Standard
Use of the Patient Benefit Index to monitor treatment of chronic spontaneous urticaria with omalizumab. / Chodziuk, Astrid C.; Ghazanfar, Misbah N.; Thomsen, Simon F.
I: Dermatologic Therapy, Bind 32, Nr. 3, e12902, 2019.Publikation: Bidrag til tidsskrift › Letter › fagfællebedømt
Harvard
Chodziuk, AC, Ghazanfar, MN & Thomsen, SF 2019, 'Use of the Patient Benefit Index to monitor treatment of chronic spontaneous urticaria with omalizumab', Dermatologic Therapy, bind 32, nr. 3, e12902. https://doi.org/10.1111/dth.12902
APA
Chodziuk, A. C., Ghazanfar, M. N., & Thomsen, S. F. (2019). Use of the Patient Benefit Index to monitor treatment of chronic spontaneous urticaria with omalizumab. Dermatologic Therapy, 32(3), [ e12902]. https://doi.org/10.1111/dth.12902
Vancouver
Chodziuk AC, Ghazanfar MN, Thomsen SF. Use of the Patient Benefit Index to monitor treatment of chronic spontaneous urticaria with omalizumab. Dermatologic Therapy. 2019;32(3). e12902. https://doi.org/10.1111/dth.12902
Author
Bibtex
@article{49d9fbd679644ac5bb4d5d6f84eed85b,
title = "Use of the Patient Benefit Index to monitor treatment of chronic spontaneous urticaria with omalizumab",
author = "Chodziuk, {Astrid C.} and Ghazanfar, {Misbah N.} and Thomsen, {Simon F.}",
year = "2019",
doi = "10.1111/dth.12902",
language = "English",
volume = "32",
journal = "Dermatologic Therapy",
issn = "1396-0296",
publisher = "Wiley-Blackwell",
number = "3",
}
RIS
TY - JOUR
T1 - Use of the Patient Benefit Index to monitor treatment of chronic spontaneous urticaria with omalizumab
AU - Chodziuk, Astrid C.
AU - Ghazanfar, Misbah N.
AU - Thomsen, Simon F.
PY - 2019
Y1 - 2019
U2 - 10.1111/dth.12902
DO - 10.1111/dth.12902
M3 - Letter
C2 - 30964569
VL - 32
JO - Dermatologic Therapy
JF - Dermatologic Therapy
SN - 1396-0296
IS - 3
M1 - e12902
ER -
ID: 226113285